Common genetic variant association with altered HLA expression, synergy with pyrethroid exposure, and risk for Parkinson's disease: An observational and case-control study

Parkinson's Disease

Volumn 1, Issue , 2015, Pages

  Kannarkat, G T ^a   Cook, D A ^a   Lee, J K ^a   Chang, J ^a   Chung, J ^a   Sandy, E ^a   Paul, K C ^b   Ritz, B ^b   Bronstein, J ^c   Factor, S A ^a   Boss, J M ^a   Tansey, M G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA DQ ANTIGEN; INSECTICIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PYRETHROID;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BLOOD CELL; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FLOW CYTOMETRY; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HLA SYSTEM; HOMOZYGOSITY; HUMAN; IMMUNE RESPONSE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MONOCYTE; OBSERVATIONAL STUDY; PARKINSON DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84955722920     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1038/npjparkd.2015.2     Document Type: Article

References (49)

1. Ross OA. A prognostic view on the application of individualized genomics in Parkinson's disease. Curr Genet Med Rep 2013; 1: 52-57.
2. Factor SA, Weiner WJ. Parkinson's Disease: Diagnosis and Clinical Management, 2nd edn. Demos Medical Publishing: New York, USA, 2007.
3. Barnum CJ, Tansey MG. Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson's disease? Curr Neurol Neurosci Rep 2012; 12: 350-358.
4. Bower JH, Maraganore DM, Peterson BJ, McDonnell SK, Ahlskog JE, Rocca WA. Head trauma preceding PD: a case-control study. Neurology 2003; 60: 1610-1615.
5. Hatcher JM, Pennell KD, Miller GW. Parkinson's disease and pesticides: a toxicological perspective. Trends Pharmacol Sci 2008; 29: 322-329.
6. Taetzsch T, Block ML. Pesticides, microglial NOX2, and Parkinson's disease. J Biochem Mol Toxicol 2013; 27: 137-149.
7. Kanthasamy A, Jin H, Anantharam V, Sondarva G, Rangasamy V, Rana A et al. Emerging neurotoxic mechanisms in environmental factors-induced neurodegeneration. Neurotoxicology 2012; 33: 833-837.
8. Waldburger JM, Masternak K, Muhlethaler-Mottet A, Villard J, Peretti M, Landmann S et al. Lessons from the bare lymphocyte syndrome: molecular mechanisms regulating MHC class II expression. Immunol Rev 2000; 178: 148-165.
9. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010; 37: 510-518.
10. Saunders JA, Estes KA, Kosloski LM, Allen HE, Dempsey KM, Torres-Russotto DR et al. CD4+regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J Neuroimmune Pharmacol 2012; 7: 927-938.
11. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V et al. Infiltration of CD4+lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009; 119: 182-192.
12. Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE et al. Non-steroidal antiinflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. Cochrane Database Syst Rev 2011, CD008454.
13. Bower JH, Ritz B. Is the answer for Parkinson disease already in the medicine cabinet? Unfortunately not. Neurology 2011; 76: 854-855.
14. Luckheeram RV, Zhou R, Verma AD, Xia B. CD4(+)T cells: differentiation and functions. Clin Dev Immunol 2012; 2012: 925135.
15. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 2010; 42: 781-785.
16. Guo Y, Deng X, Zheng W, Xu H, Song Z, Liang H et al. HLA rs3129882 variant in Chinese Han patients with late-onset sporadic Parkinson disease. Neurosci Lett 2011; 501: 185-187.
17. Ahmed I, Tamouza R, Delord M, Krishnamoorthy R, Tzourio C, Mulot C et al. Association between Parkinson's disease and the HLA-DRB1 locus. Mov Disord 2012; 27: 1104-1110.
18. Hill-Burns EM, Factor SA, Zabetian CP, Thomson G, Payami H. Evidence for more than one Parkinson's disease-associated variant within the HLA region. PloS One 2011; 6: e27109.
19. Wissemann WT, Hill-Burns EM, Zabetian CP, Factor SA, Patsopoulos N, Hoglund B et al. Association of Parkinson's disease with structural and regulatory variants in the HLA region. Am J Hum Genet 2013; 93: 984-993.
20. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009; 41: 1303-1307.
21. International Parkinson Disease Genomics C, Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011; 377: 641-649.
22. Sun C, Wei L, Luo F, Li Y, Li J, Zhu F et al. HLA-DRB1 alleles are associated with the susceptibility to sporadic Parkinson's disease in Chinese Han population. PloS One 2012; 7: e48594.
23. Latourelle JC, Dumitriu A, Hadzi TC, Beach TG, Myers RH. Evaluation of Parkinson disease risk variants as expression-QTLs. PloS One 2012; 7: e46199.
24. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 2014; 46: 989-993.
25. Zhao Y, Gopalai A, Ahmad-Annuar A, Teng E, Prakash K, Tan L et al. Association of HLA locus variant in Parkinson's disease. Clin Genet 2013; 84: 501-504.
26. Puschmann A, Verbeeck C, Heckman MG, Soto-Ortolaza AI, Lynch T, Jasinska- Myga B et al. Human leukocyte antigen variation and Parkinson's disease. Parkinsonism Relat Disord 2011; 17: 376-378.
27. Hill-Burns EM, Wissemann WT, Hamza TH, Factor SA, Zabetian CP, Payami H. Identification of a novel Parkinson's disease locus via stratified genome-wide association study. BMC Genomics 2014; 15: 118.
28. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
29. Jacob EL, Gatto NM, Thompson A, Bordelon Y, Ritz B. Occurrence of depression and anxiety prior to Parkinson's disease. Parkinsonism Relat Disord 2010; 16: 576-581.
30. Wang A, Costello S, Cockburn M, Zhang X, Bronstein J, Ritz B. Parkinson's disease risk from ambient exposure to pesticides. Eur J Epidemiol 2011; 26: 547-555.
31. Cockburn M, Mills P, Zhang X, Zadnick J, Goldberg D, Ritz B. Prostate cancer and ambient pesticide exposure in agriculturally intensive areas in California. Am J Epidemiol 2011; 173: 1280-1288.
32. Corsini E, Sokooti M, Galli CL, Moretto A, Colosio C. Pesticide induced immunotoxicity in humans: a comprehensive review of the existing evidence. Toxicology 2013; 307: 123-135.
33. Morrison G QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies 2006.
34. Chen H, Huang X, Guo X, Mailman RB, Park Y, Kamel F et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010; 74: 878-884.
35. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003; 60: 1059-1064.
36. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002; 52: 276-284.
37. Boss JM. Regulation of transcription of MHC class II genes. Curr Opin Immunol 1997; 9: 107-113.
38. Collins T, Korman AJ, Wake CT, Boss JM, Kappes DJ, Fiers W et al. Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci USA 1984; 81: 4917-4921.
39. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004; 363: 1783-1793.
40. Choi NM, Majumder P, Boss JM. Regulation of major histocompatibility complex class II genes. Curr Opin Immunol 2011; 23: 81-87.
41. Sant AJ, Chaves FA, Leddon SA, Tung J. The control of the specificity of CD4 T cell responses: thresholds, breakpoints, and ceilings. Front Immunol 2013; 4: 340.
42. Tao X, Constant S, Jorritsma P, Bottomly K. Strength of TCR signal determines the costimulatory requirements for Th1 and Th2 CD4+T cell differentiation. J Immunol 1997; 159: 5956-5963.
43. Taneja V, David CS. Role of HLA class II genes in susceptibility/resistance to inflammatory arthritis: studies with humanized mice. Immunol Rev 2010; 233: 62-78.
44. Costa C, Rapisarda V, Catania S, Di Nola C, Ledda C, Fenga C. Cytokine patterns in greenhouse workers occupationally exposed to alpha-cypermethrin: an observational study. Environ Toxicol Pharmacol 2013; 36: 796-800.
45. Righi DA, Xavier FG, Palermo-Neto J. Effects of type II pyrethroid cyhalothrin on rat innate immunity: a flow cytometric study. Int Immunopharmacol 2009; 9: 148-152.
46. Bloomquist JR, Barlow RL, Gillette JS, Li W, Kirby ML. Selective effects of insecticides on nigrostriatal dopaminergic nerve pathways. Neurotoxicology 2002; 23: 537-544.
47. Cremer JE, Cunningham VJ, Ray DE, Sarna GS. Regional changes in brain glucose utilization in rats given a pyrethroid insecticide. Brain Res 1980; 194: 278-282.
48. Doherty JD, Morii N, Hiromori T, Ohnishi J. Pyrethroids and the striatal dopaminergic system in vivo. Comp Biochem Physiol C 1988; 91: 371-375.
49. Esa AH, Warr GA, Newcombe DS. Immunotoxicity of organophosphorus compounds. Modulation of cell-mediated immune responses by inhibition of monocyte accessory functions. Clin Immunol Immunopathol 1988; 49: 41-52.